Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869923 | 1.00 | SIGMAR1 (0.44) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL6567499 | 0.82 | KDM1A (0.48) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL15305563 | 0.82 | SIGMAR1 (0.34) | SIGMAR1KDM1ANPY5R | |
| SCHEMBL7951399 | 0.78 | CYP3A4 (0.44) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL9868507 | 0.78 | CYP2C9 (0.42) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL21559876 | 0.76 | DRD2 (0.37) | KDM1A | |
| SCHEMBL29587519 | 0.75 | POLA1 (0.51) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL4984411 | 0.75 | POLA1 (0.51) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL27806303 | 0.75 | SIGMAR1 (0.38) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL4911889 | 0.74 | OPRM1 (0.42) | SIGMAR1CYP2C9TSHRCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012046253-A2 | PROCESS FOR THE PREPARATION OF N-[2- (7-METHOXY-L-NAPHTHYL) ETHYL] ACETAMIDE AND ITS NOVEL CRYSTALLINE FORMS | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | claimed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-2580189-B1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | SERVIER LAB (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| EP-2909166-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015000555-A2 | A NOVEL PROCESS FOR THE PREPARATION OF TETRALIN AND NAPHTHALENE DERIVATIVES | PHARMATHEN S.A. (GR) | 2015-01-08 | — | — | WO | disclosed |
| US-8779199-B2 | Agomelatine intermediates and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| US-8779199-B2 | Agomelatine intermediates and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| EP-2580189-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | Les Laboratoires Servier (FR) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012046253-A2 | PROCESS FOR THE PREPARATION OF N-[2- (7-METHOXY-L-NAPHTHYL) ETHYL] ACETAMIDE AND ITS NOVEL CRYSTALLINE FORMS | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011153939-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATOIRES SERVIER (FR) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011006387-A1 | PROCESS FOR PREPARING AGOMELATINE, CRYSTALS OF AGOMELATINE AND PREPARING PROCESS THEREOF | 浙江华海药业股份有限公司 (CN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | COMT, AGO2, MC5R | SIGMAR1 2750/4885CYP2C9 90/4885TSHR 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.